The Particle Size Control of "Active Encapsulation": How Liposomes, Microcapsules, and Nanoemulsions Affect Transdermal Penetration and Batch Stability

I. "Encapsulation" Is Not Just About Protecting Actives—It's a Precision Competition

In serum formulations, "encapsulation technology" frequently appears as a differentiated selling point on product pages—"liposomal Vitamin C," "nano-encapsulated retinol," "microcapsule sustained-release serum." However, most brand owners (and even some OEM factories) still limit their understanding of encapsulation to the level of "making unstable ingredients less prone to oxidation."

The truth is: the engineering core of encapsulation technology is the precise control of particle size. A liposome with a particle size of 50nm and one with 500nm look exactly the same on the ingredient list, but their transdermal penetration efficiency can differ by tens of times; their batch stability can also be worlds apart.

The global cosmetic nano-encapsulation market was valued at $2.054 billion in 2025, projected to grow to $6.203 billion by 2035, at a CAGR of 11.7%. Solid Lipid Nanoparticles (SLN/NLC) lead with a 36.4% market share, and the skincare category contributes 55.6% of the application share.

The cosmetic nanotechnology market reached $9.74 billion in 2025 and is projected to increase to $19.83 billion by 2030, at a CAGR of 15%—encapsulation technology is rapidly penetrating from the exclusive domain of professional dermatological products into the mass-market serum sector.

This is a rapidly maturing technology track. For brand owners and OEM factories, understanding how particle size affects efficacy and stability is no longer a bonus—it is the basic ticket to enter this track.

II. The Skin Is a Barrier with a Particle Size Threshold

Before discussing various encapsulation technologies, one must first understand the physical screening mechanism of the stratum corneum for particulate matter.

The Stratum Corneum (SC) is the outermost barrier of the skin, composed of about 15–20 layers of flat corneocytes arranged in a "brick-and-mortar" structure, with the intercellular spaces filled with lipid bilayers. This structure forms a strict physical barrier, and the "pass" for particles is their particle size:

A study using microfluidic synthesis of nearly monodisperse liposomes of different sizes investigated size-dependent passive transdermal transport. The results showed that large liposomes with diameters exceeding 105nm were excluded from deeper skin layers below the stratum corneum; whereas liposomes with an average diameter between 31–41nm exhibited significantly enhanced penetration. Multicolor fluorescence imaging further revealed that smaller liposomes rapidly traverse the stratum corneum without vesicle rupture.

Research on the particle size effect of curcumin nanocrystals further confirmed significant size-dependent differences in transdermal and transfollicular penetration among 60nm, 120nm, and 480nm nanocrystals. The smaller 60nm nanocrystals diffused faster, penetrated deeper, and formed a higher concentration gradient in the dermis compared to the 120nm and 480nm crystals.

This means that the particle size of the encapsulation system is the direct determinant of transdermal penetration rate, not just a simple formulation parameter:

Particle Size Range	Main Penetration Pathway	Penetration Depth	Representative Technology
<50 nm	Intercellular lipid channels	Reaches the viable epidermis	Ultra-small nano-liposomes, NLC
50–200 nm	Intercellular channels + hair follicle pathways	Mainly stays in the mid-to-lower stratum corneum	Standard liposomes, SLN
200 nm – 1 μm	Primarily relies on hair follicle pathways	Surface to upper stratum corneum	Traditional microcapsules, large liposomes
>1 μm	Skin surface, almost no penetration	Skin surface protective layer	Micron-scale encapsulation (long-term sustained release)

III. Particle Size Characteristics and Transdermal Penetration Comparison of Three Mainstream Encapsulation Technologies

Liposomes: Most Biomimetic, Particle Size Precision is Most Critical

Liposomes are spherical vesicles composed of phospholipid bilayers. Their structure is highly similar to skin cell membranes, giving them natural bio-fusion capabilities—after entering the skin, liposomes can fuse with the lipid components of corneocyte membranes to release the encapsulated active ingredients.

Smaller liposomal particles can improve transdermal drug delivery efficiency and enhance skin penetration. Research using spiral-leaf intensified co-flow focusing devices to efficiently synthesize ultra-small nano-liposomes (particle size <40nm) demonstrated superior skin penetration and retention properties, effectively encapsulating various anti-aging actives including Coenzyme Q10 while maintaining their physical characteristics.

Core Conclusions on Particle Size-Efficacy Relationship:

• <40nm: Crosses the stratum corneum without rupturing the vesicle; optimal penetration depth (viable epidermis). However, synthesis is difficult, requiring microfluidic or high-pressure homogenization equipment.

• 50–150nm: The most mature application particle size range in the industry; the optimal balance point between penetration efficiency and production feasibility.

• >200nm: Mainly stays on the skin surface; more suitable as a surface barrier repair layer rather than deep active delivery.

Key Indicator for Batch Stability — Polydispersity Index (PDI): Regulatory compliance documents for nano-cosmetics must include: particle size distribution measured by Dynamic Light Scattering (DLS), PDI values, and Zeta potential data, which must be recorded for every production batch. Stability data must prove that nano-level characteristics (particle size, PDI) remain within specifications throughout the shelf life.

PDI is the most critical quality parameter for evaluating liposome batch consistency:

• PDI < 0.2: Highly uniform particle size distribution; excellent batch stability (Industry Gold Standard).

• PDI 0.2–0.4: Moderate particle size distribution; acceptable but requires enhanced stability monitoring.

• PDI > 0.4: Overly broad particle size distribution; large batch quality variance; not recommended for commercialized products.

In actual production, the liposome preparation method directly affects PDI: the thin-film hydration method usually yields a high PDI (>0.3), while high-pressure homogenization or microfluidics can stably control the PDI between 0.1 and 0.15.

Solid Lipid Nanoparticles / Nanostructured Lipid Carriers (SLN / NLC): Best Stability, Ideal for Unstable Actives

Solid Lipid Nanoparticles (SLN) are composed of solid lipids (such as beeswax, stearic acid). Nanostructured Lipid Carriers (NLC) introduce liquid oils into the solid lipid, forming a disordered crystal structure. This subtle structural difference brings significant efficacy differences:

Parameter	SLN	NLC
Lipid Structure	Highly ordered crystals	Partially disordered, contains liquid oil phase
Active Encapsulation Rate	Lower (limited crystal interstitial space)	Higher (disordered structure provides large space)
Active Leakage Risk	Higher (crystal rearrangement squeezes it out)	Lower
Transdermal Enhancement	Moderate	High (Occlusive effect + liquid oil phase penetration promotion)
Protection for Retinol	Good	Excellent (Liquid phase buffers degradation)

Lipid nanoparticles (SLN/NLC) dominate the cosmetic nano-encapsulation market with a 36.4% share, steadily driving demand growth for anti-aging skincare and sunscreen formulations containing retinoids, vitamins, and UV filters between 2025 and 2030.

The core advantage of NLC lies in its full-process protection of extremely unstable actives (Retinol, Vitamin C): the solid lipid shell provides a physical barrier against oxidation during storage, while the liquid oil phase softens and releases upon contact with body temperature on the skin—achieving an efficacy delivery design of "high stability during storage, efficient release during use."

Nanoemulsions: Most Flexible Penetration Pathway, Most Scalable Production

Nanoemulsions are thermodynamically stable emulsification systems formed by the action of high-energy emulsification (high-pressure homogenization, ultrasound, microfluidics) on oil and water phases, with particle sizes typically between 20–200nm.

Liposomes encapsulating CoQ10 composed of soybean phosphatidylcholine and α-tocopherol achieved approximately a 2-fold increase in skin penetration; nanoemulsions and nanoemulsion gels, in comparative studies with colloidal suspensions, demonstrated higher local skin penetration efficiency.

Core Formulation Advantages of Nanoemulsions over Liposomes:

• Higher Stability: Thermodynamically stable; no phospholipid oxidation issues like liposomes.

• Stronger Production Scalability: High-pressure homogenization can be directly scaled up; batch-to-batch variance is smaller.

• Better Compatibility with Oil-Soluble Actives: Directly dissolved in the oil phase; no complex encapsulation steps required.

Impact of Particle Size on Nanoemulsion Stability: The kinetic stability of nanoemulsions (preventing Ostwald ripening and coalescence) is closely related to particle size. Nanoemulsions with a particle size <100nm can maintain stability for 6–12 months at room temperature; whereas when the particle size is >200nm, the Ostwald ripening rate accelerates, and the product will show obvious particle size growth and layering trends within its shelf life.

IV. Engineering Tools for Particle Size Control: How to Achieve Precise Preparation at the Factory Level

Understanding the impact of particle size on efficacy and stability leads to the next question for formulation engineers: How to achieve and maintain the target particle size in actual production?

1. High Pressure Homogenization (HPH): Applies extremely high pressure of 200–1000 bar to the crude emulsion, causing particles to undergo intense shear and cavitation in narrow orifices, breaking them apart. This is the most mainstream industrial technology for preparing SLN, NLC, and nanoemulsions, capable of stably controlling particle size at 50–200nm with PDI <0.2. The flaw is the oxidation risk for heat-sensitive ingredients (like Vitamin C); operation under nitrogen protection is recommended.

2. Ultrasonic Emulsification: Suitable for small-batch R&D and sampling stages; particularly effective for liposome preparation. However, ultrasonic energy is difficult to scale linearly, and consistency in mass production is inferior to HPH.

3. Microfluidics: The most precise particle size control technology, with PDI achievable below 0.05. It is the exclusive method for preparing ultra-small liposomes (<50nm). Costs are high; currently mainly used for high-end professional skincare and dermocosmetic-level products, with the economics of mass production still being optimized.

V. Regulatory Compliance: 2026 Declaration Requirements for Cosmetic Nano-Ingredients

In the EU, nano-cosmetics must be pre-notified through the Cosmetic Products Notification Portal (CPNP). The declaration documents must include: batch measurement data of DLS particle size distribution, PDI values, and Zeta potential; a complete INCI ingredient list with CAS numbers and supplier qualification certificates; and accelerated and real-time stability data proving that nano-level characteristics remain stable throughout the shelf life. While the FDA under the MoCRA framework does not yet have specific nano-clauses, it has established a framework that can implement specific nano-requirements in the future; preparing DLS verification data and technical documents in advance can save brand owners significant emergency compliance costs.

This means: brands that have chosen the nano-encapsulation technology path need to simultaneously establish a complete particle size Quality Control (QC) documentation system during the product development stage, rather than waiting to supplement data at the declaration stage.

Does your formulator treat encapsulation as a system, not a line item?

encapsulation rarely fails on its own — it fails against the rest of the system: pH, emulsifier, preservative and packaging. We assess it in context, before it costs you a sampling round.

Our R&D group works from a formulation platform that maps compatibility ahead of prototyping, which shortens the loop between brief and stable sample.

By collaborating with Explore our formulation and R&D capability you gain access to industry-leading expertise and innovative formulations that set your brand apart in the competitive global market. Send your target actives and claims; we will flag the compatibility risks before any sample is made.